For example, another clinical trial based on the mutant isocitrate dehydrogenase type 1 (IDH1) for recurrent grade II astrocytoma (NCT02193347) has shown greater efficacy [45]; the mutant IDH1 is carried by more than 70% of diffuse grade II and III gliomas [46]. Here, IDH1 is linked to astrocytoma (excluding glioblastoma).